Core Viewpoint - The company is undergoing a continuous innovation transformation, with multiple innovative pipelines being launched internationally, leading to an upward revision of revenue and profit forecasts for 2026 while maintaining profit forecasts for 2025 and 2027 [1] Group 1: Financial Analysis - The revenue projections for 2025, 2026, and 2027 are adjusted to 76.3 billion, 100.3 billion, and 110.4 billion respectively, up from previous estimates of 76.3 billion, 91.0 billion, and 110.4 billion [1] - The net profit attributable to the parent company for 2025, 2026, and 2027 is revised to 11.5 billion, 16.5 billion, and 16.6 billion respectively, compared to earlier estimates of 11.5 billion, 13.8 billion, and 16.6 billion [1] - The corresponding EPS for 2025, 2026, and 2027 is adjusted to 0.44, 0.64, and 0.64 respectively, up from previous estimates of 0.44, 0.53, and 0.64 [1] Group 2: Product Development - The company received a milestone payment of 40 million USD from AbbVie for SIM0500 on February 3, 2026, following a licensing agreement signed in January 2025 [1] - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing strong T-cell cytotoxic effects against multiple myeloma cells [2] - The FDA granted SIM0500 a fast track designation for use in patients with multiple myeloma who have received at least three prior lines of therapy and are resistant or intolerant to standard treatments [2] Group 3: Strategic Partnerships - Since 2025, the company has successfully licensed four pipelines internationally, including agreements with AbbVie, NextCure, Ipsen, and Boehringer Ingelheim, with potential total payments reaching up to 10.6 billion USD and 10.16 billion EUR [3] - The partnerships with major multinational corporations (MNCs) validate the company's enhanced innovation capabilities and suggest ongoing opportunities for new business development in the future [3]